Vertiflex, Inc. Appoints Michael Enxing to Vice President, Chief Commercial Officer

IN.PACT AV Drug-Coated Balloon Is First and Only to Show Superior and Sustained Results Through Two Years Compared to PTA in Treating Arteriovenous Fistulae Lesions

The data, which were presented virtually as a podium first at the 2021 Charing Cross Symposium, demonstrated that the IN.PACT™ AV drug-coated balloon (DCB) is the first and only DCB to show sustained and superior effectiveness through two years compared to standard percutaneous transluminal angioplasty (PTA) in end-stage renal disease (ESRD) patients with de novo or non-stented restenotic native arteriovenous fistulae (AVF) in the upper extremity.

Martell Diagnostic Laboratories Announces HERTEST: Groundbreaking Way to Detect Effectiveness of Breast Cancer RX Globally

HERTEST is a blood test that looks for a protein called human epidermal growth factor receptor (HER2), which is shed into the blood stream of patients with growing breast cancer tumors.

ESPRIT CAM Improves Productivity for Long Part Machining by Automating Multi-spindle Program Creation

ESPRIT CAM: New computer-aided-manufacturing (CAM) technology has been introduced by ESPRIT CAM, part of Hexagon’s Manufacturing Intelligence division that provides manufacturers with the control and flexibility needed to use multi-spindle and multi-channel computer-numerical-control (CNC) machinery for the machining of long parts.

Vertiflex, Inc., a leading innovator of advanced, minimally invasive interventions for spinal stenosis, today announced the appointment of Michael Enxing as Vice President and Chief Commercial Officer. Mr. Enxing will be responsible for leading all aspects of the company’s Sales, Marketing, Health Economics/Reimbursement and Professional Education strategies, related to the already successful launch of the Superion® Indirect Decompression System for the treatment of lumbar spinal stenosis.

Michael Enxing brings over 20 years of successful global leadership experience in product commercialization in the medical device, spinal and chronic pain fields. Most recently, Michael served as Vice President of Sales at Nevro Corporation where he led the company to impressive growth both internationally and domestically over the previous four years. Prior to Nevro, he served as Vice President of Sales and Marketing for Vertos Medical, and has held various executive positions at Cardiovascular Systems, Inc. (f/k/a Cardio Vascular Solutions CSI); Advanced Neuromodulation Systems, Inc. (acquired by St. Jude Medical, Inc.); Stryker Corporation; and Tecnol Medical Products, Inc. (acquired by Kimberly Clark) . Michael is a graduate of Iowa State University with a B.S. in Communications and focus in Business Administration.

Earl R. Fender, President & Chief Executive Officer of Vertiflex, said “We are very pleased to have attracted an executive of Michael’s caliber into our organization. Michael is a visionary leader who understands sales and marketing execution, market dynamics, critical organizational metrics, and cultural drivers that deliver team success and ensures the best customer engagement experiences possible. We are confident that Michael’s track record of significantly scaling businesses, will add considerable value to Vertiflex, our investors, physician providers, and most of all to patients, who will benefit from Superion’s demonstrated and durable clinical and safety profile.”

Mr. Enxing said, “I’m proud to join the Vertiflex team. As a result of the company’s achievements in product development, Level I clinical evidence generation, earning a PMA approval and Category I reimbursement for Superion, the stage is set to build a large, high growth, new category in spine that is focused on compelling clinical outcomes for patients and their physicians. Based on my prior experience in commercializing an early generation product for lumbar spinal stenosis, I believe Superion, having significant published peer-reviewed data, is positioned as the best-in-class minimally invasive solution for lumbar spinal stenosis that will also compare well to open surgical decompression in treating patients suffering from LSS.”



Related Articles